Tag
The TSLP-blocking antibody met its goals in a Phase 3 eosinophilic esophagitis trial, setting up a potential third indication and a challenge to Sanofi’s Dupixent.
The Tokyo AI firm and Julien Orts’s NMR lab will combine machine learning with atomic-resolution spectroscopy to target intrinsically disordered proteins in cancer.
Definium’s dissolving LSD tablet beat placebo in a large trial for generalized anxiety disorder, with effects seen within days — sending its shares up.
In the 106-patient HOPE-3 trial, boys and young men on deramiocel lost arm and elbow function markedly slower than those on placebo, ahead of an August FDA decision.
The partnership pairs miRecule’s RNA-design platform with peptide-based delivery to reach tissues current RNA therapies struggle to treat, starting with neuromuscular disease.
From a whole-genome map built on over a trillion lab-grown neurons, the partners pinpointed a novel neuro target in 15 months — the first payoff from a collaboration worth up to $12 billion.
The Series B will fund Phase 2 and Phase 3 studies of dotinurad, a uric-acid-lowering therapy already approved in several Asian markets.